ZF2001

ZF2001
Logo
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Trade namesZifivax
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.[2][3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.[4][5]

ZF2001 employs technology similar to other protein-based vaccines[6] in Phase III trials from Novavax, Vector Institute, and Medicago.[7]

ZF2001 was first approved for use in Uzbekistan and later China.[8][9] Production capacity is expected to be one billion doses a year in China[10] and 200 million in Uzbekistan.[11] By July, 100 million doses had been administered in China and Uzbekistan.[12]

Medical uses

It is administered in three doses over a period of two months.[10]

Efficacy

In August 2021, preliminary data from a phase III study with 28,500 participants indicated an overall efficacy of 82% against disease of any severity. Efficacy was 93% against the Alpha variant and 78% against the Delta variant.[13][14]

In July 2021, lab studies showed ZF2001 retained neutralizing effects against B.1.429 (Epsilon), B.1.351(Beta), P.1(Gamma), B.1.525(Eta), B.1.617.1(Kappa), the neutralizing titers decreased ranging from 1.1 fold to 2.1 fold, but the neutralizing efficacy were still good.[15]

Manufacturing

According to industry experts, production for this kind of vaccine is stable and reliable, and easier to achieve large-scale industrial production at home and overseas. However it was noted it can be very inconvenient for people to come back for a second and third dose.[10] Subunit vaccines are delivered alongside adjuvants and booster doses may be required.[16]

The company's vaccine manufacturing facility was put into use in September.[17] In February 2021, management said the company had an annual production capacity of 1 billion doses.[10]

In July 2021, an agreement was reached to produce the vaccine in Uzbekistan starting with 10 million doses a month and eventually 200 million doses a year.[11]

History

Clinical trials

Phase I and II trials and results

In June 2020, Longcom began a double-blind, randomized, placebo parallel controlled Phase I trial with 50 participants aged 18–59 in Chongqing divided into low-dose, high-dose, and placebo groups.[18]

In July, Longcom began a randomized, double-blind, placebo-controlled Phase II trial with 900 participants aged 18–59 in Changsha, Hunan divided into low-dose, high-dose, and placebo groups.[19] In August, an additional Phase II trial was launched with 50 participants aged 60 and above.[20][2]

In Phase II results published in The Lancet, on the two-dose schedule, seroconversion rates of neutralizing antibodies after the second dose were 76% (114 of 150 participants) in a 25 μg group and 72% (108 of 150) in a 50 μg group. On the three-dose schedule, seroconversion rate of neutralizing antibodies after the third dose were 97% (143 of 148 participants) in the 25 μg group and 93% (138 of 148) in the 50 μg group. 7 to 14 days after the administration of the third dose, the GMTs of neutralizing antibodies reached levels that were significantly higher than observed in human convalescent serum of recovering COVID-19 patients, especially in the 25 μg group.[21]

Phase III trials

In December 2020, Longcom began enrollment of a Phase III randomized, double-blind, placebo-controlled clinical trial for 29,000 participants, including 750 participants between 18-59 and 250 participants 60 and older in China and 21,000 participants between 18-59 and 7,000 participants 60 and older outside China.[22][17]

In December 2020, Malaysia's MyEG announced it would conduct Phase III trials. If the trials were successful, MyEG would be the sole distributor of ZF2001 in Malaysia for 3 years.[5]

In December 2020, Uzbekistan began a year-long Phase III trial of ZF2001 with 5,000 volunteers between 18 and 59.[23][24]

In December 2020, Ecuador's Minister of Health, Juan Carlos Zevallos announced Phase III trials would involve between 5,000 and 8,000 volunteers.[25]

In February 2021, Pakistan's Drug Regulatory Authority (DRAP) approved Phase III trials with approximately 10,000 participants to be conducted at UHS Lahore, National Defense Hospital, and Agha Khan Hospital.[26]

The vaccine is also being trialed in Indonesia.[14]

Children and adolescents trial

In July 2021, Longcom began a randomized, blinded, placebo-controlled phase I with 75 participants aged 3–17.[27][28]

In November 2021, Longcom began a phase II with 400 participants aged 3–17.[29]

Authorizations

  Full authorization
  Emergency authorization
  Allowed for travel
See also: List of COVID-19 vaccine authorizations § Zifivax

On 1 March 2021, Uzbekistan granted approval for ZF2001 (under tradename ZF-UZ-VAC 2001) after having taken part in the Phase III trials.[9] In March, Uzbekistan received 1 million doses and started vaccinations in April.[30] By June, a total of 6.5 million doses had been delivered.[31]

In March 2021, China approved of ZF2001 for emergency use after being approved by Uzbekistan earlier in the month.[8]

In June 2021, Malaysia's MyEG signed a letter of intent to purchase 10 million doses of the vaccine.[32]

On 7 September, the National Agency of Drug and Food Control of Indonesia (BPOM) published the emergency use authorization for Zifivax.[33]

On 10 January 2022, the National Agency of Drug and Food Control of Indonesia (BPOM) published the emergency use authorization for Zifivax as Booster for Sinovac.[34]

Research

As described in Cell, the CoV spike receptor-binding domain (RBD) is an attractive vaccine target for coronaviruses but is constrained by limited immunogenicity, however a dimeric form of MERS-CoV RBD offers greater protection. The RBD-dimer significantly increases neutralizing antibodies compared to a conventional monomeric form and protected mice against MERS-CoV infection. CoV RBD-dimer have been produced at high yields in pilot scale production.[35]

Rather than injecting a whole virus, subunit vaccines contains virus particles specially selected to stimulate an immune response. Because the fragments cannot cause disease, subunit vaccines are considered very safe.[16] Subunit vaccines in widespread use include the Hepatitis B vaccine and Pertussis vaccine. However, as only a few viral components are included in the vaccine which does not display the full complexity of the virus, their efficacy may be limited.[36]

References

  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ a b "Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 December 2020.
  3. ^ "COVID-19 Vaccine: ZIFIVAX by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences". covidvax.org. Archived from the original on 30 January 2021. Retrieved 27 December 2020.
  4. ^ "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. 20 November 2020. Retrieved 27 December 2020.
  5. ^ a b Ying TP (7 December 2020). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". NST Online. Retrieved 27 December 2020.
  6. ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
  7. ^ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 27 December 2020.
  8. ^ a b Liu R (15 March 2021). "China IMCAS's COVID-19 vaccine obtained emergency use approval in China". Reuters. Retrieved 15 March 2021.
  9. ^ a b Mamatkulov M (1 March 2021). "Uzbekistan approves Chinese-developed COVID-19 vaccine". Reuters. Retrieved 2 March 2021.
  10. ^ a b c d "China's production bottleneck 'could be eased with latest Covid-19 vaccine'". South China Morning Post. 17 March 2021. Retrieved 18 March 2021.
  11. ^ a b "ZF-UZ-VAC-2001 vaccine to be produced in Uzbekistan". UzDaily.uz (in Russian). Retrieved 28 July 2021.
  12. ^ Liu R (17 July 2021). "China Zhifei's COVID shot largely retains effect against Delta variant-lab study". Reuters. Retrieved 17 July 2021.
  13. ^ "China's Zhifei says unit's COVID shot shows 81.76% efficacy in late-stage trial". Reuters. 27 August 2021.
  14. ^ a b "New Chinese vaccine shows 82% effectiveness against serious Covid-19". The Straits Times. 27 August 2021. Retrieved 28 August 2021.
  15. ^ Zhao X, Zheng A, Li D, Zhang R, Sun H, Wang Q, et al. (October 2021). "Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants". The Lancet. Microbe. 2 (10): e494. doi:10.1016/S2666-5247(21)00217-2. PMC 8378832. PMID 34458880. S2CID 237246788.
  16. ^ a b "What are protein subunit vaccines and how could they be used against COVID-19?". www.gavi.org. Retrieved 27 December 2020.
  17. ^ a b "Another Chinese Covid-19 vaccine enters late-stage human trials with a plan to produce 300 million doses annually". Business Insider. Retrieved 27 December 2020.
  18. ^ Clinical trial number NCT04445194 for "Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine" at ClinicalTrials.gov
  19. ^ Clinical trial number NCT04466085 for "A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years" at ClinicalTrials.gov
  20. ^ Clinical trial number NCT04550351 for "A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above" at ClinicalTrials.gov
  21. ^ Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. (August 2021). "Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials". The Lancet. Infectious Diseases. 21 (8): 1107–1119. doi:10.1016/S1473-3099(21)00127-4. PMC 7990482. PMID 33773111.
  22. ^ Clinical trial number NCT04646590 for "A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19" at ClinicalTrials.gov
  23. ^ "Uzbekistan to carry out late-stage trial of Chinese COVID-19 vaccine candidate". Reuters. 11 November 2020. Retrieved 27 December 2020.
  24. ^ "Uzbekistan poised to start trials on Chinese COVID-19 vaccine | Eurasianet". eurasianet.org. Retrieved 27 December 2020.
  25. ^ "Ecuador participará en ensayos de una vacuna china contra el covid-19". CNN (in Spanish). 29 December 2020. Retrieved 23 January 2021.
  26. ^ "China's third vaccine enters Pakistan". The Nation. 15 February 2021. Retrieved 28 February 2021.
  27. ^ "A randomized, blinded, placebo-controlled phase I clinical trial of recombinant New Coronavirus virus vaccine (CHO cells) in the safety and tolerability of healthy people aged 3 to 17 years of age". chictr.org.cn. Chinese Clinical Trial Registry. 7 July 2021. Retrieved 7 July 2021.
  28. ^ "Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (3~17 Years Old)". clinicaltrials.gov. United States National Library of Medicine. 14 July 2021. Retrieved 14 July 2021.
  29. ^ "Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19）Vaccine (CHO Cell)". clinicaltrials.gov. United States National Library of Medicine. 5 November 2021. Retrieved 5 November 2021.
  30. ^ "Uzbekistan receives 1 million doses of ZF-UZ-VAC 2001 vaccine". Kun.uz. Retrieved 28 March 2021.
  31. ^ "Доставлен очередной миллион доз вакцины ZF-UZ-VAC2001". Газета.uz (in Russian). 30 June 2021. Retrieved 13 July 2021.
  32. ^ "MyEG signs LOI to buy 10 million doses of Anhui Zhifei Covid-19 vaccine". The Star. Retrieved 28 August 2021.
  33. ^ "BPOM Setujui Penggunaan Dalam Kedaruratan Vaksin Zifivax". Republika.co.id (in Indonesian). 7 October 2021. Retrieved 7 October 2021.
  34. ^ "BPOM Terbitkan Izin Darurat untuk Booster, Pengguna Sinovac Bisa Gunakan Vaksin Zifivax Halaman all". 10 January 2022.
  35. ^ Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. (August 2020). "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS". Cell. 182 (3): 722–733.e11. doi:10.1016/j.cell.2020.06.035. PMC 7321023. PMID 32645327.
  36. ^ Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F (October 2020). "A systematic review of SARS-CoV-2 vaccine candidates". Signal Transduction and Targeted Therapy. 5 (1): 237. doi:10.1038/s41392-020-00352-y. PMC 7551521. PMID 33051445.
Scholia has a profile for Anhui Zhifei Longcom Biopharmaceutical COVID-19 vaccine candidate (Q97154236).

Read other articles:

Dighton-Rehoboth Regional High School

High school in North Dighton, Massachusetts, United StatesDighton-Rehoboth Regional High SchoolAddress2700 Regional Rd.[2][3]North Dighton, Massachusetts 02764United StatesCoordinates41°51′09″N 71°11′46″W / 41.85250°N 71.19611°W / 41.85250; -71.19611InformationTypeHigh schoolOpen enrollment[1]MottoWe Are DREstablished1824School districtDighton-Rehoboth Regional School DistrictNCES District ID2504200[4]SuperintendentWilliam Ru...

 

 

Dana Hall School

Private school in Wellesley, Massachusetts, United StatesDana Hall SchoolAddress45 Dana RoadWellesley, Massachusetts 02181United StatesCoordinates42°17′41″N 71°17′28″W / 42.29472°N 71.29111°W / 42.29472; -71.29111InformationTypePrivateMottoAmor CaritasEstablished1881; 143 years ago (1881)Head of schoolKatherine BradleyGrades5-12Enrollment473Campus size52 acres (210,000 m2)[1]Campus typeSuburbanColor(s)   Blue and whi...

 

 

حسان البجاوي

حسان البجاوي   معلومات شخصية الميلاد 14 فبراير 1975 (49 سنة)  بنزرت  الطول 189 سنتيمتر  مركز اللعب حارس مرمى  الجنسية تونس  المسيرة الاحترافية  سنواتفريقمبارياتأهداف1994–2002 النادي الرياضي البنزرتي -2002–2005 الملعب التونسي -2005–2006 النادي الرياضي البنزرتي 24 (0)2006–...

NA-244 Karachi West-I

Constituency of the National Assembly of Pakistan NA-244 Karachi West-IConstituencyfor the National Assembly of PakistanRegionManghopir Town (partly) of Karachi West District in KarachiElectorate155,824 [1]Current constituencyCreated30 November 2023Member(s)Farooq SattarCreated fromNA-243 Karachi-V NA-244 Karachi West-I (این اے-244،کراچی مغربی-1) is a constituency for the National Assembly of Pakistan.[2] Area This constituency includes following Karachi neighb...

 

 

Liberalism in Japan

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article is in list format but may read better as prose. You can help by converting this article, if appropriate. Editing help is available. (October 2017) This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional ...

 

 

Muhammad Prasetyo

Drs. H.Muhammad PrasetyoS.H. M.H.Muhammad Prasetyo Jaksa Agung Republik Indonesia ke-23Masa jabatan20 November 2014 – 21 Oktober 2019PresidenJoko WidodoWakil PresidenMuhammad Jusuf Kalla Ma'ruf AminPendahuluAndhi Nirwanto(Pelaksana Tugas)PenggantiArminsyah (Plt.)Anggota Dewan Perwakilan Rakyat Republik IndonesiaMasa jabatan1 Oktober 2014 – 20 November 2014PresidenSusilo Bambang Yudhoyono Joko Widodo Informasi pribadiLahir9 Mei 1947 (umur 76)Tuban, Jawa Timur, In...

LEGO Marvel Super Heroes

Disambiguazione – Se stai cercando la serie di corti LEGO, vedi Cortometraggi LEGO Marvel. Questa voce o sezione sull'argomento videogiochi non è ancora formattata secondo gli standard. Contribuisci a migliorarla secondo le convenzioni di Wikipedia. Segui i suggerimenti del progetto di riferimento. LEGO Marvel Super HeroesvideogiocoPiattaformaMicrosoft Windows, PlayStation 4, PlayStation 3, PlayStation Vita, Xbox One, Xbox 360, Wii U, macOS, Nintendo D...

 

 

Exhaustion of remedies

This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (November 2020) (Learn how and when to remove this message) Administrative law of the United States General Rulemaking Notice of proposed rulemaking Adjudication Administrative law judge Code of Federal Regulations Federal Register Statutory framework Administrative Procedure Ac...

 

 

Lesbophobia

Irrational fear of, and aversion to, lesbians Soweto Pride 2012 participants remember lesbians raped and murdered in 2007. Part of a series onLesbian feminism Women's liberation movement People Paula Gunn Allen Dorothy Allison Ti-Grace Atkinson Alison Bechdel Evelyn Torton Beck Miriam Ben-Shalom Julie Bindel Ivy Bottini Charlotte Bunch Cheryl Clarke Michelle Cliff Kate Clinton Jeanne Córdova Mary Daly Max Dashu Stormé DeLarverie Diane DiMassa Alix Dobkin Andrea Dworkin Elana Dykewomon Lilli...

Toyota Ractis

Generasi keduaInformasiProdusenToyotaJuga disebutToyota Verso-SToyota Space VersoToyota Ractis Verso (Hong Kong)Subaru TreziaMasa produksi2010-2016Bodi & rangkaKelasMini MPVBentuk kerangkahatchback 5 pintuPenyalur dayaMesin1.33 L 1NR-FE1.4 L 1ND-TV TurbodieselTransmisi6-speed manual7-speed CVTDimensiJarak sumbu roda2.550 mm (100,4 in)Panjang3.990 mm (157,1 in) Toyota Ractis adalah mobil subkompak yang diproduksi oleh Toyota dan Kanto Auto Works. Ken...

 

 

Bakersfield Police Department

Police department in Bakersfield, California This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Bakersfield Police Department – news · newspapers · books · scholar&...

 

 

Deewangee

DeewangeePosterSutradaraAnees BazmeeProduserNitin ManmohanDitulis olehAnees Bazmee,Neeraj Pathak,Humayum MirzaPemeranAjay DevgnAkshaye KhannaUrmila MatondkarPenata musikIsmail DarbarSinematograferPushan KripalaniPenyuntingAshfaq-SarvarPerusahaanproduksiNeha ArtsTanggal rilis 25 Oktober 2002 (2002-10-25) Durasi169 minutesNegaraIndiaBahasaHindiAnggaran₹90 million[1]Pendapatankotor₹110 million[1]Deewangee (Inggris: Obsession) adalah sebuah film cerita seru psikolog...

Caterine Ibargüen

Caterine Ibargüen Caterine Ibargüen lors du Golden Gala de Rome en 2017. Informations Disciplines Triple saut, longueur, hauteur Période d'activité 1999 – Nationalité Colombienne Naissance 12 février 1984 (40 ans) Apartadó Taille 1,80 m (5′ 11″) [1] Masse 70 kg (154 lb)[1] Entraîneur Ubaldo Duany Records • Triple saut : 15,31 m (2014)• Saut en longueur : 6,87 m (2018)• Saut en hauteur : 1,93 m (2005) Distinctions Trop...

 

 

Boulengerula niedeni

Species of amphibian Boulengerula niedeni B. niedeni in Taita–Taveta, Kenya Conservation status Endangered  (IUCN 3.1)[1] Scientific classification Domain: Eukaryota Kingdom: Animalia Phylum: Chordata Class: Amphibia Order: Gymnophiona Clade: Apoda Family: Herpelidae Genus: Boulengerula Species: B. niedeni Binomial name Boulengerula niedeniMüller, Measey, Loader & Malonza, 2005 Boulengerula niedeni, the Sagalla caecilian, is a worm-like amphibian first described in 20...

 

 

Nemenčinė

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Nemenčinė – news · newspapers · books · scholar · JSTOR (December 2009) (Learn how and when to remove this message) City in Dzūkija, LithuaniaNemenčinėCitySculpture of Mary at the center of the city and the church FlagCoat of armsNemenčinėLocation of Nem...

Rumah Lamin

Sejumlah orang berpose di depan rumah Lamin di Desa Budaya Pampang. Rumah Lamin adalah rumah adat dari Kalimantan Timur.[1] Rumah Lamin adalah identitas masyarakat Dayak di Kalimantan Timur.[1] Rumah Lamin mempunyai panjang sekitar 300 meter, lebar 15 meter, dan tinggi kurang lebih 3 meter.[1] Rumah Lamin juga dikenal sebagai rumah panggung yang panjang dari sambung menyambung.[2] Rumah ini dapat ditinggal oleh beberapa keluarga karena ukuran rumah yang cukup b...

 

 

Berga, Thuringia

Stadtteil of Berga-Wünschendorf in Thuringia, GermanyBerga Stadtteil of Berga-Wünschendorf Coat of armsLocation of Berga Berga Show map of GermanyBerga Show map of ThuringiaCoordinates: 50°45′N 12°10′E / 50.750°N 12.167°E / 50.750; 12.167CountryGermanyStateThuringiaDistrictGreiz TownBerga-WünschendorfArea • Total43.49 km2 (16.79 sq mi)Elevation229 m (751 ft)Population (2022-12-31) • Total3,218 •...

 

 

Intractable pain

This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (August 2017) Intractable pain, also called intractable pain syndrome (IPS), is a severe, constant, relentless, and debilitating pain that is not curable by any known means and which causes a house-bound or bed-bound state and early death if not adequately treated, usually with opioids and/or interventional procedures. It is not relieved by ordinary medical,...

Paul Bélanger

Pour les articles homonymes, voir Bélanger. Ne doit pas être confondu avec Paul Béranger. Paul BélangerBiographieNaissance 1953LévisNationalité canadienneActivités Poète, écrivain, éditeurAutres informationsA travaillé pour Éditions du NoroîtUniversité du Québec à MontréalGenre artistique PoésieDistinctions Prix Alain-Grandbois (2010)Prix de poésie Gatien Lapointe - Jaime-Sabines (2018)modifier - modifier le code - modifier Wikidata Paul Bélanger est un poète et éditeur...

 

 

The End of History and the Last Man

The End of History and the Last Man PengarangFrancis FukuyamaBahasaInggrisDiterbitkan1992 (Free Press)Halaman418ISBNISBN 0-02-910975-2 The End of History and the Last Man adalah buku karya Francis Fukuyama tahun 1992 sekaligus perluasan esainya tahun 1989, The End of History?, yang diterbitkan di jurnal kajian internasional The National Interest. Dalam buku ini, Fukuyama berpendapat bahwa kelahiran demokrasi liberal Barat mungkin menandakan akhir dari evolusi sosial-budaya umat manusia dan be...